Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01687270 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
A Phase 2 study of Post Liver Transplant and Recurrent Chronic Hepatitis C Virus, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 12
- Study locations
NCT01687270: Completed Phase 2 study of Post Liver Transplant and Recurrent Chronic Hepatitis C Virus, sponsored by Gilead Sciences.
NCT01687270 is a Phase 2 study of Post Liver Transplant and Recurrent Chronic Hepatitis C Virus that has completed, run by Gilead Sciences. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01687270, a Phase 2 study of Post Liver Transplant and Recurrent Chronic Hepatitis C Virus, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an open-label, single-arm study of sofosbuvir (GS-7977) and ribavirin (RBV) in adults who have had a liver transplant which has become re-infected with hepatitis C. The treatment period is 24 weeks with up to 48 weeks of follow up. The total time in this study will last up to 72 weeks not including the screening visit.
Primary Outcome
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, \< 25 IU/mL) 12 weeks following the last dose of study drug.
Conditions Studied
Interventions
- DRUG RBV
- DRUG Sofosbuvir
Study Locations (12)
New York
- - New York
- - New York
California
- - San Francisco
Indiana
- - Indianapolis
Kansas
- - Kansas City
Massachusetts
- - Boston
Michigan
- - Ann Arbor
Minnesota
- - Rochester
Other
- - Villejuif
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT01687270 record still lists
NCT01687270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Post Liver Transplant appearing as the primary indexed condition, and to 2 interventions - of which RBV is the first listed.
NCT01687270 lists 12 locations in 11 states (New York, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT01687270 about?
NCT01687270 is a clinical study titled "Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant". This is an open-label, single-arm study of sofosbuvir (GS-7977) and ribavirin (RBV) in adults who have had a liver transplant which has become re-infected with hepatitis C. The treatment period is 24 weeks with up to 48 weeks of follow up. The total time in this study will last up to 72 weeks not in...
What is the current status of trial NCT01687270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-11. Estimated completion is 2014-08.
What conditions does trial NCT01687270 study?
This clinical trial studies the following conditions: Post Liver Transplant, Recurrent Chronic Hepatitis C Virus.
What interventions are being tested in trial NCT01687270?
The interventions under investigation include: RBV (DRUG), Sofosbuvir (DRUG).
Who is sponsoring clinical trial NCT01687270?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01687270 being conducted?
This trial has 12 study locations across California, Indiana, Kansas, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Liver Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01687270's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia